Did Sarepta Therapeutics Just Unveil a Breakthrough?

Delivery is important. It is important for e-commerce, the space economy, pizza night and especially drug development. That’s what a recent announcement from Sarepta Therapeutics does (SRPT) worth a closer look by investors.

As one of the leading genetic medicine companies in the world, Sarepta Therapeutics is at the forefront of many nerdy developments. It was the first drug developer to receive U.S. Food and Drug Administration (FDA) approval for products to treat Duchenne muscular dystrophy (DMD), a rare genetic disorder that affects muscle development. That portfolio is expected to generate net sales of at least $825 million for the full year 2022.


Be the first to comment

Leave a Reply

Your email address will not be published.